Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESURE trial of induced hypertension with norepinephrine in progressive perforating artery stroke
2023-508704-37-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of norepinephrine in ischemic stroke and lacunar infarct (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Functional independence at 90 days. Planned start Nov 2024; status: authorised.
02
Drugs
norepinephrine
03
Conditions
ischemic strokelacunar infarct
Beyond the preview
Go deeper on 2023-508704-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508704-37-00.